382 results about "Plasma rich platelet" patented technology

The PRP separator-concentrator of this invention is suitable for office use or emergency use for trauma victims. The PRP separator comprises a motorized centrifugal separation assembly, and a concentrator assembly. The centrifugal separator assembly comprises a centrifugal drum separator that includes an erythrocyte capture module and a motor having a drive axis connected to the centrifugal drum separator. The concentrator assembly comprises a water-removal module for preparing PRP concentrate. The centrifugal drum separator has an erythrocyte trap. The water removal module can be a syringe device with water absorbing beads or it can be a pump-hollow fiber cartridge assembly. The hollow fibers are membranes with pores that allow the flow of water through the fiber membrane while excluding flow of clotting factors useful for sealing and adhering tissue and growth factors helpful for healing while avoiding activation of platelets and disruption of any trace erythrocytes present in the PRP.

A PRP separator-concentrator comprising a housing, a separation assembly, and a concentration assembly. The concentration assembly has a concentration sump. An axially concentric rigid stationary outlet tube is secured to the housing and extends through the separation assembly to the sump. The separation assembly is attached to and positioned above the concentration assembly to form a combined separator-concentrator assemblage that is rotatable about the outlet tube. The separation assembly includes a separation chamber lined with a depth filter having pores and passageways that are sized to receive and entrap erythrocytes during centrifuging. The concentration chamber has a floor for supporting desiccated beads and a wall with at least one opening closed with a screen. The concentrator can have a distribution of upright screen supports, the upright screen supports having an inner surface and an outer surface, the cylindrical screen being supported on the outer surface of the upright screen supports. A stationary bead rake can be secured to the stationary tube and extend outward therefrom, the rake having distal ends that are spaced at a distance from the upright screen supports. The rake can comprise a longitudinal body, the center of which is secured to the rigid outlet tube. The separator-concentrator includes a valve assembly connecting the separation chamber and the concentration chamber. PRP concentrate is produced by contacting PRP with desiccated beads while the beads are stirred with a stationary rake, and rotating the concentration chamber at centrifugal speeds to separate PRP concentrate from the beads.

A system/analyzer-unit and method/platform—using information obtained from at least one, adapted for a plurality of, magnetoelastic sensor elements in contact with one or more samples comprising blood from a patient—for automatically quantifying one or more parameters of the patient's blood. Information obtained from emissions measured from each of the sensor elements is uniquely processed to determine a quantification about the patient's blood, such as, quantifying platelet aggregation to determine platelet contribution toward clot formation; quantifying fibrin network contribution toward clot formation; quantifying platelet-fibrin clot interactions; quantifying kinetics of thrombin clot generation; quantifying platelet-fibrin clot strength; and so on. Structural aspects of the analyzer-unit include: a cartridge having at least one bay within which a sensor element is positioned; each bay in fluid communication with both (a) an entry port for injecting a first blood sample composed of blood taken from the patient (human or other mammal), and (b) a gas vent through which air displaced by injecting the first blood sample into the bay.

Methods and kits are disclosed to promote vascularization of tissue in mammals using an autologous platelet-rich plasma composition. The kit includes components for the preparation of platelet-rich plasma from the patient's blood and components for administration to an area in need of vascularization. The methods and kits are useful for the treatment of tendinosis, and in particular, lateral epicondylitis and plantar fasciitis.

A surgical awl is disclosed for tissue repair. The surgical awl includes an internal lumen through which bioactive substances, such as platelet-rich plasma, may be delivered to a site of tissue or organ disease or dysfunction. In particular, the surgical awl is useful as a microfracture awl for cartilage repair augmented by delivery of platelet-rich plasma through the lumen of the device.

Methods are described for using compositions containing platelet-rich plasma for the treatment of a variety of tissue lesions. Particularly, delivery of platelet-rich plasma to connective tissue is described. The described method and compositions have been shown to provide both pain relief and improved mobility in treatment of lateral epicondylitis.

Methods and treatments for osteolysis employing interleukin-1 receptor antagonist (IL-1ra). Activating production of interleukin-1 receptor antagonist includes incubating adipose tissue, adipocytes, whole blood, platelet rich plasma, and/or isolated white blood cells with polyacrylamide beads to produce a solution rich in interleukin-1 receptor antagonist. Activating the production of interleukin-1 receptor antagonist includes using an implantable device loaded with adipose tissue, adipocytes, whole blood, platelet rich plasma, and/or isolated white blood cells. Methods for treating osteolysis at the site of an artificial joint in a patient include administering and/or inserting the solution rich in interleukin-1 receptor antagonist and/or the implantable device, respectively.

A semi-synthetic platelet gel comprising a platelet-rich plasma, at least one platelet activator, and a biocompatible polymer selected from the group comprising carbomers, polyalkylene glycols, poloxamers, polyesters, polyethers, polyanhydrides, polyacrylates, polyvinyl acetates, polyvinyl pyrrolidones, polysaccharides, and derivatives thereof. A method for preparing a semi-synthetic platelet gel comprising the steps of (a) mixing a platelet-rich plasma with at least one platelet activator, and, before the start of clot formation, (b) adding the mixture thus obtained to a biocompatible polymer selected from the group comprising carbomers, polyalkylene glycols, poloxamers, polyesters, polyethers, polyanhydrides, polyacrylates, polyvinyl acetates, polyvinyl pyrrolidones, polysaccharides, and derivatives thereof.

A blood separation system is fully mechanized to collect blood from a patient, separate waste portions of the blood, wash the blood, and redirect the usable portions to a device for reinjecting the usable portions into the patient. The system provides screen displays with detailed setup instructions and instructs the operator at the appropriate times to do certain manual steps. Apparatus for sequestration of platelet rich plasma spins at a high speed sufficient to separate solid cells from the blood sample and then spins at a lower speed for a predetermined time to allow platelets to elute from the solid cells.

A composition and method for enhancing tissue growth, regeneration, and repair includes a Biological Glue formed by extraction of an Extremely Platelet Rich Plasma (EPRP) derived from whole blood, and subsequent activation and clotting. The Biological Glue may be utilized alone to fill defects or may be used as an adhesive agent for other biological and non-biological materials. These materials may include processed thrombus derived from the activation of EPRP. Additionally, the Extremely Platelet Rich Plasma may be impregnated with directly harvested or cultured cells, including stem cells, or other materials, prior to activation, to form a Biological Implant that may be implanted in vivo. A Platelet Factor Enriched Serum (PFS) derived from the activation of the Extremely Platelet Rich Plasma (EPRP) may be added to the cell cultures in preparation of a Biological Implant, in order to provide additional growth factors that speed the development of the cell cultures.

A particle/cell separation device is described which is particularly adapted for neutrophil depletion from a preparation of whole blood or platelet-rich plasma. Also described are blood and platelet rich plasma compositions produced using the device which are neutrophil-depleted.

A novel centrifuge bowl for processing particles suspended in a fluid is disclosed. The centrifuge bowl includes an annular cavity concentrically located about the rotation axis for suitably separating particles of similar densities but of different diameters. The cavity is preferably configured to have an annular cross sectional area, which is parallel to the rotation axis, that increases from a centrifugal side of the cavity toward a centripetal side of the cavity. This configuration allows to generate an almost rigidly rotating field upon rotation of the centrifuge bowl, which field helps to uniformly disperse Coriolis force throughout the circumference of the cavity to avoid turbulent mixing of the particles. In an alternative embodiment, the cavity is surrounded by an outer cavity for separating particles according to density before processing them through the inner cavity. This construction is particularly suitable for processing whole blood to harvest platelet-rich-plasma with reduced level of white blood cell contamination.

A blood component such as platelets are concentrated from the blood. The concentrate such as platelet-rich plasma is used in a cell culture medium to grow and proliferate cells. The cells may be from the same person from which the blood concentrate is obtained. The cells grown in the culture medium may be used to treat a patient which may be the same patient from which the blood was extracted and/or the cells were obtained.

Methods and kits for treating a cardiac arrhythmia using a platelet rich plasma (PRP) composition are provided. Any type of arrhythmia may be treated using the PRP composition. The PRP composition may comprise PRP developed using blood collected from a patient suffering the cardiac arrhythmia. The PRP composition may be buffered to a physiological pH and may include one or more anti-arrhythmic agents, anti-coagulants, or other drugs. The PRP composition may be delivered using a nebulizer, minimally invasively, or surgically. In some embodiments, the PRP composition may be coated on one or more medical devices. The PRP composition may be delivered to an identified portion of the electrical conduction system of the heart affected and/or causing the arrhythmia to occur.

A microchip comprising therein a first channel which allows inflow of a first liquid selected from whole blood, platelet-rich plasma and a drug-treated liquid thereof, a second channel connected to the first channel, which allows inflow of a second liquid containing an agent that is reactive with the first liquid, and a merged channel extended from the connection portion of the first channel with the second channel, wherein, in the merged channel, a stirring section having a stirring bar for mixing the first liquid with the second liquid is provided; and a blood monitoring device using the same.

A composition, method, and use of microporous particles such as polysaccharide hemostat particle gels activates platelet rich plasma (PRP) or other platelet-containing substances. The composition may contain microporous polysaccharaide hemostats (MPH) mixed with platelet-rich plasma, platelet-poor plasma, blood, or the like. The method may contain mixing the MPH with platelet-rich plasma or other platelet-containing substance either by hand, in a device, or by applying the MPH directly to the wound before or after application of the platelet-containing substance. Alternatively, MPH can by applied directly to the bleeding wound, using the blood as a source of platelets.

The invention relates to a photosensitive PRP (platelet-rich plasma) gel and a preparation method and application thereof. The preparation method comprises the following steps of mixing a biocompatible medium solution of a macromolecule modified by an o-nitrobenzyl photo response group and an extracted PRP according to a certain ratio, so as to form a gel precursor solution; then, radiating the gel precursor solution by light, and enabling the o-nitrobenzyl group in the macromolecule modified by the o-nitrobenzyl photo response group to generate photochemical reaction under the excitation action of a light source, so as to produce an aldehyde functional group; generating coupling reaction with amino distributed at the surface of the protein in the PRP to form an imine bond, so as to realize the preparation of the photosensitive PRP gel. Compared with the prior art, the photosensitive PRP gel prepared by the method has the advantages that the internal cell factors can be slowly released, and the tight and seamless bonding between the PRP gel and wounds is realized.

The present invention discloses one kind of injected bone repairing material and its preparation and application. The injected bone repairing material consists of solution I and solution II, the solution I is the mixture of platelet rich plasma (PRP) and 80-100 mg/ml concentration fibrinogen solution in the ratio of 1 to 3-6; and the solution II is solution mixture of calcium chloride in 40 mmol/ml concentration and thrombin in 400-1000 U/ml concentration. When the injected bone repairing material is used, solution I and solution II in the volume ratio of 1-9 are sucked with two syringes and injected into body to form gel with high adhesive force, with PRP accounting for 10-30 vol%. The injected bone repairing material is used in preparing implant for treating bone defect and bone nonunion and promoting fracture healing.

An object of this invention is to provide platelet-rich plasma having high activity easily and at low cost. The object is achieved by a method for preparing platelet-rich plasma comprising a step of adding a water-soluble polymer compound to whole blood obtained by blood collection. For example, by adding poly-L-glutamic acid to whole blood and allowing the mixture to stand still for a definite period, it is possible to obtain platelet-rich plasma having high activity that contains blood plasma components containing much fibrinogen in addition to platelets in the supernatant and blood cell components including white blood cells. This invention also includes the platelet-rich plasma and the use thereof as well as a kit for preparing platelet-rich plasma.